News | October 22, 2025
Cambrex to invest $120 million to expand API manufacturing in US
Expanding US operations to address the increased demand for API development and manufacturing
Expanding US operations to address the increased demand for API development and manufacturing
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The new plant will manufacture high-quality Type I borosilicate glass tubing
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Investment to expand manufacturing and global medicine supply capacity
Subscribe To Our Newsletter & Stay Updated
